SCHEMBL2847392

SCHEMBL2847392

[CH](c1ccccc1)n1cccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
MAOB P27338 2/20 0.39
TSHR P16473 1/20 0.39
CYP2A6 P11509 1/20 0.39
LMNA P02545 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NFE2L2 Q16236 1/20 0.33
CYP19A1 P11511 1/20 0.33
MAOA P21397 1/20 0.33
TRPA1 O75762 1/20 0.33
ALOX5 P09917 1/20 0.33
MAPK1 P28482 1/20 0.33
MAPT P10636 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
HDAC3 O15379 1/20 0.32
TNKS O95271 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HCAR2 Q8TDS4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2490075 0.72 CYP3A4 (0.45) TSHRLMNACYP19A1MAPTMEN1
SCHEMBL1177108 0.65 ALDH1A1 (0.43) ALDH1A1CYP2A6LMNAMAPTMEN1
SCHEMBL8386424 0.65 MEN1 (0.47) ALDH1A1MAOBTSHRCYP2A6LMNA
SCHEMBL947117 0.63 HPGD (0.46) ALDH1A1TSHRCYP2A6LMNAMAPT
(Z)-1,2-Diphenylethene SCHEMBL817116 0.61 ALDH1A1 (0.53) ALDH1A1MAOBTSHRCYP2A6LMNA
(Z)-1,2-Diphenylethene SCHEMBL9134296 0.61 MAOB (0.73) ALDH1A1MAOBLMNANFE2L2CYP19A1
(Z)-1,2-Diphenylethene SCHEMBL443 0.61 MAOB (0.73) ALDH1A1MAOBLMNANFE2L2CYP19A1
(Z)-1,2-Diphenylethene SCHEMBL22712863 0.61 MAOB (0.73) ALDH1A1MAOBLMNANFE2L2CYP19A1
(Z)-1,2-Diphenylethene SCHEMBL21847984 0.61 MAOB (0.73) ALDH1A1MAOBLMNANFE2L2CYP19A1
(Z)-1,2-Diphenylethene SCHEMBL9134305 0.61 MAOB (0.73) ALDH1A1MAOBLMNANFE2L2CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137402-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2010-06-03 US claimed
US-7687537-B2 N-[(4,5-diphenyl-2-thienyl)methyl]amine derivatives, their preparation and their therapeutic application SANOFI-AVENTIS (FR) 2010-03-30 US claimed
CN-101128451-A N- [ (4, 5-diphenyl-2-thienyl) methyl ] amine derivatives, their preparation and therapeutic use SANOFI AVENTIS (FR) 2008-02-20 CN claimed
US-20080009543-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2008-01-10 US claimed
US-20100137402-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2010-06-03 US disclosed
US-7687537-B2 N-[(4,5-diphenyl-2-thienyl)methyl]amine derivatives, their preparation and their therapeutic application SANOFI-AVENTIS (FR) 2010-03-30 US disclosed
CN-101128451-A N- [ (4, 5-diphenyl-2-thienyl) methyl ] amine derivatives, their preparation and therapeutic use SANOFI AVENTIS (FR) 2008-02-20 CN disclosed
US-20080009543-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2008-01-10 US disclosed
EP-1858872-A1 DERIVATIVES OF N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, THIOUREA AND UREA) AS CANNABINOID CB1 RECEPTOR ANTAGONISTS Sanofi-Aventis (FR) 2007-11-28 EP disclosed
WO-2006084975-A1 DERIVATIVES OF N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, THIOUREA AND UREA) AS CANNABINOID CB1 RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009543-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION CNR1, CNR2, GPR18 ALDH1A1 3274/4885MAOB 686/4885TSHR 323/4885
US-20100137402-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION CNR1, CNR2, GPR18 ALDH1A1 3274/4885MAOB 686/4885TSHR 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.